GSTM1 and anemia (phenotype): The APPLY study (A Prospective Aranesp® Observational Study in Patients with Chemotherapy-Induced Anemia) found that 80.7% of patients were initiated on darbepoetin alfa treatment within the Hb range of 9–11 g/dL, indicating that treatment of patients with chemotherapy-induced anemia is generally congruent with the Romanian recommendations.